Prostate Proteomics
How LC-MS/MS analysis is being employed to identify better biomarkers in high-risk prostate cancer patients

Prostate cancer is the fifth leading cause of death among men in western countries, but identifying high-risk individuals with current diagnostic tools is difficult – in part because of the heterogeneous nature of the disease. Although a number of studies have looked at genomic and transcriptomic alterations in prostate cancer, they have not previously been linked to changes at the proteome level.
With a plan to connect the dots, a team of researchers assessed key changes in PCa tissue during tumor progression (
Though more work is needed, the researchers believe that the NDUFS1 and ATP50 proteins may serve as novel prognostic markers for the identification of high-risk PCa patients.
Image Credit: National Cancer Institute, National Institutes of Health
- R Wiebringhaus et al., Cancers, 13, 6036 (2021). DOI: 10.3390/cancers13236036